DDInter1485 DDInter1376
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Polatuzumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Polatuzumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Polatuzumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secnidazole
Polatuzumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Polatuzumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Polatuzumab vedotin may lead to a major life threatening interaction when taken with Clarithromycin
Polatuzumab vedotin may lead to a major life threatening interaction when taken with Upadacitinib